替莫西林对比碳青霉烯类治疗西班牙三代头孢耐药肠杆菌菌血症:多中心3期非劣效随机试验
ASTARTÉ试验在西班牙29家医院纳入328例三代头孢耐药肠杆菌菌血症患者,随机接受替莫西林或碳青霉烯类治疗。严重不良事件两组分别为19%和24%。
要点
- 替莫西林对三代头孢耐药肠杆菌菌血症的28天临床成功率非劣效于碳青霉烯类。
- 替莫西林组临床成功120/163(74%),碳青霉烯组121/165(73%)。
- 严重不良事件替莫西林组19%、碳青霉烯组24%,安全性可接受。
核心结论
- 在三代头孢耐药肠杆菌菌血症的靶向治疗中,替莫西林对碳青霉烯类达到非劣效。
- 结果支持替莫西林作为该场景下有效且安全的碳青霉烯替代选择。
研究设计与样本
- 多中心、3期、开放标签、非劣效、随机、实用性、研究者发起的临床试验,在西班牙29家医院开展。
- 纳入≥18岁、三代头孢耐药肠杆菌单一菌种菌血症、对美罗培南和替莫西林敏感且需≥4天有效静脉治疗的患者。
- 1:1随机分配至替莫西林2g每8小时静脉给药或美罗培南1g每8小时(适当时可用厄他培南1g每日),按既往有效药物和感染来源分层。
- 主要终点为改良意向治疗人群(mITT)第28天临床成功,非劣效界值10%。
主要发现
- mITT人群年龄中位72岁(IQR 65-80),女性106例(32%),男性222例(68%),Charlson合并症指数中位2(IQR 0-4)。
- 严重不良事件替莫西林组31/163(19%),碳青霉烯组35/165(24%)。
关键数值与推荐
- 主要终点临床成功定义为临床治愈、无需因不良事件或临床失败停药或换药、无复发且第28天存活。
- 非劣效界值设为10%,采用95%CI下限与界值比较。
- 替莫西林给药方案为2g每8小时静脉滴注。
临床怎么用
- 对三代头孢耐药肠杆菌菌血症且病原对替莫西林敏感者,可考虑替莫西林替代碳青霉烯类进行靶向治疗。
- 替莫西林为窄谱β-内酰胺,有望减少碳青霉烯类选择压力。
局限性
- 开放标签设计,未设盲。
- 仅纳入对美罗培南和替莫西林均敏感的菌株,结果外推需谨慎。
- 研究在西班牙29家医院开展,其他地区适用性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alternatives to carbapenems for the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E) are urgently needed to reduce the selection pressure posed by these drugs. Temocillin is a neglected narrow-spectrum β-lactam. The aim of the trial was to investigate if temocillin is non-inferior to carbapenems for the targeted treatment of bacteraemia due to 3GCR-E. METHODS: This multicentre, phase 3, open-label, non-inferiority, randomised, pragmatic, investigator-initiated clinical trial was conducted in 29 Spanish hospitals. We randomly assigned patients with bacteraemia caused by 3GCR-E to receive intravenous temocillin (2 g every 8 h) or meropenem (1 g every 8 h; or ertapenem [1 g per day] if appropriate). Patients aged 18 years or older were eligible if they had monomicrobial bacteraemia due to any 3GCR-E that was susceptible to meropenem and temocillin and treatment for at least 4 days with an active intravenous drug was considered necessary. Randomisation (1:1) was stratified according to previous active drug and to source of infection; no blocks were used. The primary endpoint was clinical success (clinical cure, no need to stop or change the study drug because of adverse event or clinical failure, absence of recurrence, and survival by day 28) in all randomly assigned patients who received at least one dose of a study drug (modified intention-to-treat population [mITT]). Adverse events were assessed in the mITT population. No missing data were reported. A 10% non-inferiority margin was established. The trial was registered in ClinicalTrials.gov (NCT04478721) and is complete and closed to new participants. FINDINGS: 334 eligible patients were enrolled between Dec 15, 2020, and Nov 29, 2024, of whom 328 were included in the mITT population (163 assigned temocillin and 165 assigned carbapenems). In 328 participants, the median age was 72 years (IQR 65-80), 106 (32%) were female, 222 (68%) were male, and the median Charlson Comorbidity Index was 2 (IQR 0-4). In the mITT population, clinical success occurred in 120 (74%) of 163 patients assigned temocillin and 121 (73%) of 165 patients assigned carbapenems (difference 0·3% [95% CI -7·7 to ∞]; non-inferiority p=0·017). Serious adverse events were reported in 31 (19%) of 163 patients assigned temocillin and 35 (24%) of 165 patients assigned carbapenems. INTERPRETATION: In patients with bacteraemia caused by 3GCR-E, temocillin was non-inferior to carbapenems as targeted treatment. These findings support the use of temocillin as an effective and safe alternative to carbapenems in this setting. FUNDING: Instituto de Salud Carlos III.
引用
- Dezza FC, Pulido LB, Borreguero IB, et al. Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial. Lancet. 2026. PMID: 42425122. doi:10.1016/S0140-6736(26)00760-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。